Miist Therapeutics has made it possible for it to emerge as a pathbreaker in inhaled therapy. This is based on the fusion of physics with pharmaceutical science so that it produces an effective therapy and, simultaneously, quick relief to the patients. The just concluded $7 million funding is the greatest stride by the company so far as investors show trust in the firm’s pioneering strategy.

Miist Therapeutics is a firm founder & ceo Dalton Signor and is headquartered in Alameda, California. The company focuses on the development of inhaled medicines based on a physics-based methodology for enhancing drug delivery and efficacy. Miist’s core technology relies on ultrasonic vibration to create 2-micron aqueous drug particles that are delivered deep into the peripheral lung for rapid absorption into the bloodstream.

Miist Therapeutics is a physics-based developer of inhaled medicines which today announced it has raised $7M seed funding led by Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First and California Innovation Fund among others. 

Read also: Robeauté has raised $28M to advance development of neurosurgical microrobots

Miist had clinically validated the approach and the company is pushing two assets through: MST-01 for treating smoking addiction, and MST-02 for the treatment of migraine. They showed the efficacy of MST-01 at Phase 1, bringing fast effects by Miist’s therapies once they achieve 92% symptom relief in 2 minutes after dosing.

The innovation center of Miist Therapeutics revolves around its proprietary inhaler technology. This particular device uses ultrasonic vibration in the generation of fine, 2-micron aqueous drug particles, which are said to reach peripheral lung regions in a rapid, efficient manner that would be readily absorbed into the bloodstream.

That is different from the traditional delivery systems used with inhalation therapy, which primarily use larger particle sizes that cause them to tend to deposit into the central airways, producing slower absorption and onset of action.

Read also: FastWave Medical Secures $19M to Advance Intravascular Lithotripsy Systems

Current Active Projects

Miist is currently advancing two major therapeutic projects:

• MST-01: Smoking Cessation – The MST-01 is to give an instant control over nicotine craving. Using a fast-acting formulation, which will be delivered via an inhaler, the therapy hopes to replicate the swift delivery of nicotine by cigarettes that will help users break their addiction.
• Target relief in migrainewith MST-02. Migraine remedyMST-02 is engineered to provide migraine patients with an almost instant migraine symptom relief treatment. Miist’s inhalation delivery technology creates the opportunity to allow patients experiencing an acute episode of migraine onset to have pain relief much quicker.

Miist Therapeutics has received clinical validation for its approach, having proven the safety and efficacy of its inhaler technology in the delivery of therapeutic agents. Focusing on conditions that require the rapid relief of symptoms, this company has enormous potential to bridge gaps in treatment paradigms.

Read also: Axial3D Secures $18.2 Million to Revolutionize Personalized Surgical Solutions

Market Potential

The therapeutic areas targeted by Miist represent substantial market opportunities:

• Smoking Cessation: Even with increased awareness regarding the dangers posed by smoking, nicotine addiction still is an everyday phenomenon. Cessation drugs such as nicotine patches and chewing gum cannot quickly provide the addictive drug and often do not serve their purpose at the optimum level. The possibility of providing fast relief places MST-01 among the best hopes for smoking quitters.
• Migraine Treatment: Migraines plague millions worldwide, and most patients seek rapid treatments to address acute attacks. Existing oral drugs have delayed onset times because of their absorption process in the gastrointestinal tract. An inhaled delivery mechanism for MST-02 will bring about an immediate onset of action, revolutionizing acute migraine treatment.

Future Directions

Having secured the funding, Miist Therapeutics intends to

• Advance Clinical Trials: Continue the clinical development of MST-01 and MST-02 with the goal of providing strong evidence of safety and efficacy.
• Pipeline Expansion: Explore new therapeutic areas where rapid drug delivery may result in significant clinical advantages.
• Enhance Technology: Continue to optimize the inhaler platform to further improve drug delivery and patient experience.
• Regulatory Engagement: Maintain dialogue with regulatory agencies to ensure compliance and accelerate the approval of its therapies.